Cargando…

Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin

At diagnosis 10–25% of patients with colorectal liver metastases (CRLM) present as resectable disease. Liver resection is the gold standard treatment, resulting in a 5-year overall survival (OS) of 22–58%, local recurrence rates of 1.2–10.4% and a perioperative mortality of less than 5%. Multiple at...

Descripción completa

Detalles Bibliográficos
Autores principales: Hompes, D., Prevoo, W., Ruers, T.
Formato: Texto
Lenguaje:English
Publicado: e-Med 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080126/
https://www.ncbi.nlm.nih.gov/pubmed/21435988
http://dx.doi.org/10.1102/1470-7330.2011.0004
_version_ 1782202079807275008
author Hompes, D.
Prevoo, W.
Ruers, T.
author_facet Hompes, D.
Prevoo, W.
Ruers, T.
author_sort Hompes, D.
collection PubMed
description At diagnosis 10–25% of patients with colorectal liver metastases (CRLM) present as resectable disease. Liver resection is the gold standard treatment, resulting in a 5-year overall survival (OS) of 22–58%, local recurrence rates of 1.2–10.4% and a perioperative mortality of less than 5%. Multiple attempts have been made to assess the possible contribution of radiofrequency ablation (RFA) to improve OS and progression-free survival (PFS) in patients with unresectable colorectal liver metastases. The aim of this paper is to review the RFA literature in the setting of colorectal liver metastases: RFA with and without chemotherapy, RFA with and without resection, RFA for solitary unresectable CRLM, surgical and percutaneous imaging-guided RFA, RFA compared with chemotherapy. The reported OS, PFS, local recurrence rates, morbidity and mortality in these different settings are analyzed. This paper reflects on a possible role of RFA in resectable CRLM.
format Text
id pubmed-3080126
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher e-Med
record_format MEDLINE/PubMed
spelling pubmed-30801262013-03-24 Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin Hompes, D. Prevoo, W. Ruers, T. Cancer Imaging Review At diagnosis 10–25% of patients with colorectal liver metastases (CRLM) present as resectable disease. Liver resection is the gold standard treatment, resulting in a 5-year overall survival (OS) of 22–58%, local recurrence rates of 1.2–10.4% and a perioperative mortality of less than 5%. Multiple attempts have been made to assess the possible contribution of radiofrequency ablation (RFA) to improve OS and progression-free survival (PFS) in patients with unresectable colorectal liver metastases. The aim of this paper is to review the RFA literature in the setting of colorectal liver metastases: RFA with and without chemotherapy, RFA with and without resection, RFA for solitary unresectable CRLM, surgical and percutaneous imaging-guided RFA, RFA compared with chemotherapy. The reported OS, PFS, local recurrence rates, morbidity and mortality in these different settings are analyzed. This paper reflects on a possible role of RFA in resectable CRLM. e-Med 2011-03-24 /pmc/articles/PMC3080126/ /pubmed/21435988 http://dx.doi.org/10.1102/1470-7330.2011.0004 Text en © 2011 International Cancer Imaging Society
spellingShingle Review
Hompes, D.
Prevoo, W.
Ruers, T.
Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
title Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
title_full Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
title_fullStr Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
title_full_unstemmed Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
title_short Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
title_sort radiofrequency ablation as a treatment tool for liver metastases of colorectal origin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080126/
https://www.ncbi.nlm.nih.gov/pubmed/21435988
http://dx.doi.org/10.1102/1470-7330.2011.0004
work_keys_str_mv AT hompesd radiofrequencyablationasatreatmenttoolforlivermetastasesofcolorectalorigin
AT prevoow radiofrequencyablationasatreatmenttoolforlivermetastasesofcolorectalorigin
AT ruerst radiofrequencyablationasatreatmenttoolforlivermetastasesofcolorectalorigin